 |
 Video: What is a Stock Split?
|
|
|
| Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease. According to our Atara Biotherapeutics stock split history records, Atara Biotherapeutics has had 0 splits. | |
|
Atara Biotherapeutics (ATRA) has 0 splits in our Atara Biotherapeutics stock split history database.
Looking at the Atara Biotherapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Atara Biotherapeutics shares, starting with a $10,000 purchase of ATRA, presented on a split-history-adjusted basis factoring in the complete Atara Biotherapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/17/2014 |
|
| End date: |
04/19/2024 |
|
| Start price/share: |
$12.00 |
|
| End price/share: |
$0.66 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-94.49% |
|
| Average Annual Total Return: |
-26.27% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$550.79 |
|
| Years: |
9.51 |
|
|
|
|
|
